Market Access Fighting fake GLP-1s to protect patients & preserve trust Counterfeit drug promotion is a patient safety, brand equity, and public trust issue.
Market Access Capital discipline in biotech: Building enduring companies w... Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.
Market Access Highlights from the UK’s December 2025 VPAG metrics Leela Barham looked at the latest metrics used to monitor the UK’s voluntary pricing scheme.
Market Access For life sciences, it’s not only about when to bring on a GC... For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.
Market Access A step forward, but not the finish line: What NICE’s QALY up... Healthcare in the UK is at an inflection point.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
News CHMP backs Novo's haemophilia A drug Frehemgo Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
